UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 12, 2007

 

SIRTRIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33465

20-1410189

(State or other jurisdiction of

(Commission

(I.R.S. Employer

of incorporation or organization)

File Number)

Identification No.)

 

 

790 Memorial Drive, Cambridge, Massachusetts 02139

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code:    (617) 252-6920

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 


 

Item 2.02

Results of Operations and Financial Condition.

On November 12, 2007, Sirtris Pharmaceuticals, Inc. issued a press release relating to its results of operations and financial conditions for the quarter ended September 30, 2007. A copy of the press release is furnished as Exhibit 99.1 to this form 8-K.

 

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

99.1

Press Release issued by Sirtris Pharmaceuticals, Inc. on November 12, 2007.

 

 

2


 

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SIRTRIS PHARMACEUTICALS, INC.

 

 

 

 

 

Date: November 14, 2007

By:

/s/ CHRISTOPH WESTPHAL

 

 

Name:

Christoph Westphal

 

 

Title:

President and Chief Executive Officer

 

 

 

3


 

Index to Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release issued by Sirtris Pharmaceuticals, Inc. on November 12, 2007.

 

 

4

Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.